Abstracts

Vaccination against Neisseria meningitidis serogroup B (MenB) has significantly aided the global efforts against invasive meningococcal…

During the COVID-19 pandemic, non-pharmaceutical interventions suppressed the circulation of many respiratory viruses, including…

The following selected highlights spotlight several interesting and timely abstracts presented at the 2023 European Congress of Clinical…

Radiomics has been proven effective for the characterisation of primary prostate cancer (PCa).1,2 However, the limited interpretability of the proposed models represents one of the major limitations in this field.

Renal cell carcinoma (RCC) is the most common malignant kidney tumour, with clear cell RCC (ccRCC) accounting for 70–80% of all cases. Approximately 15–20% of patients have primary metastatic RCC at diagnosis, and 15–20% of those who receive curative treatment for localised tumours will experience recurrence within 5 years of follow-up.

Urothelial carcinoma in situ (CIS) of the bladder is an intra-epithelial, high grade, malignant neoplasm characterised by flat (non-papillary) growth, with high probability of disease progression.

To retrospectively evaluate the safety and efficacy of CT-guided percutaneous microwave ablation (MWA) of small-sized (≤2 cm) hepatocellular carcinoma (HCC) regarding therapy response and survival rates. The goal is to compare data from minimal invasive treatments like MWA and radiofrequency ablation in comparison to surgical resection or data from liver transplantation.

The high incidence of bone metastases, particularly vertebral metastases, in patients with cancer and the limitations of conventional treatments are the main challenge for the interventional oncology specialty.